Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial
ConclusionsBuspirone reduces CO2 chemosensitivity and improves CA and oxygen saturation across the 24  h in patients with HF. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 30, 2021 Category: Cardiology Authors: Alberto Giannoni, Chiara Borrelli, Gianluca Mirizzi, George B. Richerson, Michele Emdin, Claudio Passino Tags: Research article Source Type: research

Buspirone Dose-Response on Facilitating Forelimb Functional Recovery in Cervical Spinal Cord Injured Rats
In this study, we investigated the dose-response of Buspirone treatment on reaching and grasping function in cervical cord injured rats. Seventeen adult Sprague-Dawley rats were trained to reach and grasp sugar pellets before a C4 bilateral dorsal column crush injury. After 1 week post-injury, the rats were divided into 3 groups to receive 1 of 3 different dosages of Buspirone (i.p., 1 dose/day: 1.5, n = 5; 2.5, n = 6 and 3.5 mg/kg b.w., n = 6). Forelimb reaching and grip strength test were recorded once per week, within 1 hour of Buspirone administration for 11 weeks post-injury. Different dose groups began to exhibit dif...
Source: Dose Response - March 15, 2021 Category: Drugs & Pharmacology Authors: Rakib Uddin Ahmed V Reggie Edgerton Shuai Li Yong-Ping Zheng Monzurul Alam Source Type: research

Buspirone Dose-Response on Facilitating Forelimb Functional Recovery in Cervical Spinal Cord Injured Rats
In this study, we investigated the dose-response of Buspirone treatment on reaching and grasping function in cervical cord injured rats. Seventeen adult Sprague-Dawley rats were trained to reach and grasp sugar pellets before a C4 bilateral dorsal column crush injury. After 1 week post-injury, the rats were divided into 3 groups to receive 1 of 3 different dosages of Buspirone (i.p., 1 dose/day: 1.5, n = 5; 2.5, n = 6 and 3.5 mg/kg b.w., n = 6). Forelimb reaching and grip strength test were recorded once per week, within 1 hour of Buspirone administration for 11 weeks post-injury. Different dose groups began to exhibit dif...
Source: Dose Response - March 15, 2021 Category: Drugs & Pharmacology Authors: Rakib Uddin Ahmed V Reggie Edgerton Shuai Li Yong-Ping Zheng Monzurul Alam Source Type: research

Buspirone Dose-Response on Facilitating Forelimb Functional Recovery in Cervical Spinal Cord Injured Rats
In this study, we investigated the dose-response of Buspirone treatment on reaching and grasping function in cervical cord injured rats. Seventeen adult Sprague-Dawley rats were trained to reach and grasp sugar pellets before a C4 bilateral dorsal column crush injury. After 1 week post-injury, the rats were divided into 3 groups to receive 1 of 3 different dosages of Buspirone (i.p., 1 dose/day: 1.5, n = 5; 2.5, n = 6 and 3.5 mg/kg b.w., n = 6). Forelimb reaching and grip strength test were recorded once per week, within 1 hour of Buspirone administration for 11 weeks post-injury. Different dose groups began to exhibit dif...
Source: Dose Response - March 15, 2021 Category: Drugs & Pharmacology Authors: Rakib Uddin Ahmed V Reggie Edgerton Shuai Li Yong-Ping Zheng Monzurul Alam Source Type: research

Buspirone Dose-Response on Facilitating Forelimb Functional Recovery in Cervical Spinal Cord Injured Rats
In this study, we investigated the dose-response of Buspirone treatment on reaching and grasping function in cervical cord injured rats. Seventeen adult Sprague-Dawley rats were trained to reach and grasp sugar pellets before a C4 bilateral dorsal column crush injury. After 1 week post-injury, the rats were divided into 3 groups to receive 1 of 3 different dosages of Buspirone (i.p., 1 dose/day: 1.5, n = 5; 2.5, n = 6 and 3.5 mg/kg b.w., n = 6). Forelimb reaching and grip strength test were recorded once per week, within 1 hour of Buspirone administration for 11 weeks post-injury. Different dose groups began to exhibit dif...
Source: Dose Response - March 15, 2021 Category: Drugs & Pharmacology Authors: Rakib Uddin Ahmed V Reggie Edgerton Shuai Li Yong-Ping Zheng Monzurul Alam Source Type: research

Buspirone Dose-Response on Facilitating Forelimb Functional Recovery in Cervical Spinal Cord Injured Rats
In this study, we investigated the dose-response of Buspirone treatment on reaching and grasping function in cervical cord injured rats. Seventeen adult Sprague-Dawley rats were trained to reach and grasp sugar pellets before a C4 bilateral dorsal column crush injury. After 1 week post-injury, the rats were divided into 3 groups to receive 1 of 3 different dosages of Buspirone (i.p., 1 dose/day: 1.5, n = 5; 2.5, n = 6 and 3.5 mg/kg b.w., n = 6). Forelimb reaching and grip strength test were recorded once per week, within 1 hour of Buspirone administration for 11 weeks post-injury. Different dose groups began to exhibit dif...
Source: Dose Response - March 15, 2021 Category: Drugs & Pharmacology Authors: Rakib Uddin Ahmed V Reggie Edgerton Shuai Li Yong-Ping Zheng Monzurul Alam Source Type: research

Use of psychiatric medication by college students: A decade of data
AbstractObjectivesGiven the rising prevalence of psychiatric symptomatology among college students, this analysis aims to identify temporal trends in psychiatric medication usage.MethodsThis analysis used data from the Healthy Minds Study Survey administered between 2007 and 2019, yielding a sample of 320,817 university students. Survey data were examined via descriptive analyses.ResultsOver the last decade from 2007 to 2018 –2019, there was an increase in use of nearly all classes of psychiatric medications, with reported antidepressant medication (selective serotonin reuptake inhibitors [SSRIs], serotonin‐norepin...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - March 5, 2021 Category: Drugs & Pharmacology Authors: Marcia R. Morris, Carolin C. Hoeflich, Sara Nutley, Vicki L. Ellingrod, Michelle B. Riba, Catherine W. Striley Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Use of Psychiatric Medication by College Students: A Decade of Data
AbstractObjectivesGiven the rising prevalence of psychiatric symptomatology among college students, this analysis aims to identify temporal trends in psychiatric medication usage.MethodsThis analysis used data from the Healthy Minds Study Survey administered between 2007 and 2019, yielding a sample of 320,817 university students. Survey data was examined via descriptive analyses.ResultsOver the last decade from 2007 to 2018 ‐2019, there was an increase in use of nearly all classes of psychiatric medications, with reported antidepressant medication (selective serotonin reuptake inhibitors (SSRIs), serotonin‐norepinephri...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 14, 2021 Category: Drugs & Pharmacology Authors: Marcia R. Morris, Carolin C. Hoeflich, Sara Nutley, Vicki L. Ellingrod, Michelle B. Riba, Catherine W. Striley Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Serotonin 1A agonist and cardiopulmonary improvements with whole-body exercise in acute, high-level spinal cord injury: a retrospective analysis
AbstractPurposeHigh-level spinal cord injury (SCI) can result in spinal and supraspinal respiratory control deficits leading to insufficient ventilatory responses to exercise and training-related adaptations. We hypothesized a serotonin agonist, known to improve respiratory function in animal models, would improve adaptations to whole-body functional electrical stimulation (FES) exercise training in patients with acute high-level SCI.MethodsWe identified 10 patients (
Source: European Journal of Applied Physiology - February 1, 2021 Category: Physiology Source Type: research

Buspirone for functional improvement after acute traumatic spinal cord injury: a propensity score-matched cohort study
Spinal Cord, Published online: 25 January 2021; doi:10.1038/s41393-020-00606-0Buspirone for functional improvement after acute traumatic spinal cord injury: a propensity score-matched cohort study (Source: Spinal Cord)
Source: Spinal Cord - January 25, 2021 Category: Research Authors: James W. Morgan Ryan Solinsky Source Type: research

A case of a pediatric patient after a large ingestion of buspirone
. (Source: Clinical Toxicology)
Source: Clinical Toxicology - January 15, 2021 Category: Toxicology Authors: James R. Krenz Anita Chary Kevin R. Schwartz Bryan D. Hayes Michael E. O ’Brien Source Type: research

Serotonergic Facilitation of Forelimb Functional Recovery in Rats with Cervical Spinal Cord Injury
AbstractSerotonergic agents can improve the recovery of motor ability after a spinal cord injury. Herein, we compare the effects of buspirone, a 5-HT1A receptor partial agonist, to fluoxetine, a selective serotonin reuptake inhibitor, on forelimb motor function recovery after a C4 bilateral dorsal funiculi crush in adult female rats. After injury, single pellet reaching performance and forelimb muscle activity decreased in all rats. From 1 to 6  weeks after injury, rats were tested on these tasks with and without buspirone (1–2 mg/kg) or fluoxetine (1–5 mg/kg). Reaching and grasping success rates...
Source: Neurotherapeutics - January 8, 2021 Category: Neurology Source Type: research

Buspirone Abuse by Insufflation: A Case Report
No abstract available (Source: Journal of Clinical Psychopharmacology)
Source: Journal of Clinical Psychopharmacology - December 28, 2020 Category: Psychiatry Tags: Letters to the Editors – Case Reports Source Type: research

Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Anxiety disorders are the most prevalent psychiatric disorders and a leading cause of disability. While there continues to be expansive research in posttraumatic stress disorder (PTSD), depression and schizophrenia, there is a relative dearth of novel medications under investigation for anxiety disorders. This review's first aim is to summarize current pharmacological treatments (both approved and off-label) for panic disorder (PD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and specific phobias (SP), including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibi...
Source: Frontiers in Psychiatry - December 23, 2020 Category: Psychiatry Source Type: research

Buccal buspirone as add – on therapy to omeprazole versus omeprazole in treatment of ...
Proton pump inhibitors (PPIs) are recommended as first line treatments for gastroesophageal reflux disease (GERD). Failure to PPIs has been mentioned as a problem in pharmacotherapy of GERD. The present study compared the symptom relief, quality of life (QoL) and adverse drug reactions (ADRs) of omeprazole plus buccal buspirone with that of omeprazole alone.This was a prospective, randomized trial between buccal buspirone (10 mg/d) plus omeprazole (20 mg/d) and omeprazole (20 mg/d) plus placebo administered for 4 weeks to patients with GERD symptoms. Patients who had GERD symptoms enrolled in this study.67 patients were ra...
Source: Iranian Journal of Pharmaceutical Research - December 20, 2020 Category: Drugs & Pharmacology Source Type: research

The buspirone-dependent abdominal pain transmission within the nucleus tractus solitarius in the rat
Publication date: Available online 26 November 2020Source: NeuroscienceAuthor(s): Sergey S. Panteleev, Ivan B. Sivachenko, Olga A. Lyubashina (Source: Neuroscience)
Source: Neuroscience - November 26, 2020 Category: Neuroscience Source Type: research

Neonatal pain modulates in adolescent rats the antinociceptive effects of fluoxetine and buspirone administrated to their depressive dams during gestation.
NEONATAL PAIN MODULATES IN ADOLESCENT RATS THE ANTINOCICEPTIVE EFFECTS OF FLUOXETINE AND BUSPIRONE ADMINISTRATED TO THEIR DEPRESSIVE DAMS DURING GESTATION. Can J Physiol Pharmacol. 2020 Nov 13;: Authors: Butkevich IP, Mikhailenko VA, Vershinina EA Abstract Previously, we have shown that the administration of a selective serotonin reuptake inhibitor fluoxetine or a 5-HT1A receptor agonist buspirone to stressed rats during gestation causes in the offspring alleviation of formalin-induced pain, strengthened by prenatal stress. We have also found that neonatal inflammatory pain strengthens formalin-induce...
Source: Canadian Journal of Physiology and Pharmacology - November 13, 2020 Category: Drugs & Pharmacology Authors: Butkevich IP, Mikhailenko VA, Vershinina EA Tags: Can J Physiol Pharmacol Source Type: research

Buccal buspirone as add – on therapy to omeprazole versus omeprazole in treatment of ...
Proton pump inhibitors (PPIs) are recommended as first line treatments for gastroesophageal reflux disease (GERD). Failure to PPIs has been mentioned as a problem in pharmacotherapy of GERD. The present study compared the symptom relief, quality of life (QoL) and adverse drug reactions (ADRs) of omeprazole plus buccal buspirone with that of omeprazole alone.This was a prospective, randomized trial between buccal buspirone (10 mg/d) plus omeprazole (20 mg/d) and omeprazole (20 mg/d) plus placebo administered for 4 weeks to patients with GERD symptoms. Patients who had GERD symptoms enrolled in this study.67 patients were ra...
Source: Iranian Journal of Pharmaceutical Research - October 31, 2020 Category: Drugs & Pharmacology Source Type: research

A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability
In Parkinson's disease (PD), anxiety is common, associated with lower health-related quality of life, and undertreated. The primary objective of this study was to determine the tolerability of buspirone for the treatment of anxiety in PD. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - October 12, 2020 Category: Neurology Authors: Ruth B. Schneider, Peggy Auinger, Christopher G. Tarolli, Julia Iourinets, Mar ía Cristina Gil-Díaz, Irene H. Richard Source Type: research

Efficacy of Buspirone Augmentation of Escitalopram in Patients with Major Depressive Disorder with and without Atypical Features: A Randomized, 8 Week, Multicenter, Open-Label Clinical Trial.
CONCLUSION: Buspirone augmentation did not demonstrate significant benefits in MDD patients; however, buspirone augmentation showed greater efficacy for the improvement of cognitive function in MDD patients without atypical features. Our study suggests that atypical features are an important factor for cognitive enhancement in buspirone augmentation treatment in patients with MDD. PMID: 32750760 [PubMed - as supplied by publisher] (Source: Psychiatry Investigation)
Source: Psychiatry Investigation - August 13, 2020 Category: Psychiatry Tags: Psychiatry Investig Source Type: research

Effects of Stress Exposure during Adolescent Period on Inflammatory Pain Response, Psychoemotional Behavior, and Action of Antidepressants in Prenatally Stressed Adult Male Rats
We studied the effects of stress exposure during the adolescent period of development (SAPD) on the parameters of inflammatory painful response and the level of depression-like behavior in prenatally stressed adult male rats. In addition, we analyzed the effects of selective serotonin (5-HT) reuptake inhibitor fluoxetine and 5-HT1A receptor agonist buspirone injected chronically to pregnant mothers for correction of behavioral disturbances caused by prenatal stress in their adult male progeny. In the formalin test, SAPD decreased integrated at the supraspinal level pain-like response that was increased by prenatal stress; ...
Source: Bulletin of Experimental Biology and Medicine - August 2, 2020 Category: Biology Source Type: research

Non-acid Reflux: When It Matters and Approach to Management
AbstractPurpose of ReviewThis narrative review focuses on the presentation, contributing factors, diagnosis, and treatment of non-acid reflux. We also propose algorithms for diagnosis and treatment.Recent FindingsThere is a paucity of recent data regarding non-acid reflux. The recent Porto and Lyon consensus statements do not fully address non-acid reflux or give guidance on classification. However, recent developments in the lung transplantation field, as well as older data in the general population, argue for the importance of non-acid reflux.SummaryExtrapolating from the Porto and Lyon consensus, we generally classify p...
Source: Current Gastroenterology Reports - July 9, 2020 Category: Gastroenterology Source Type: research

Antidepressant Augmentation: A Review of the Literature and a Review of the Pharmacoeconomic Considerations
Purpose Antidepressant augmentation strategies for treatment-resistant depression (TRD) are discussed here with an analysis of patient out-of-pocket costs for various medications. The choice of agent ranges from newer atypical antipsychotics (aripiprazole, brexpiprazole, quetiapine) to older agents including buspirone, liothyronine (T3), and lithium. We sought to better understand the differences among these agents to aid in clinical decision making. Methods We conducted a focused review of the support for each of the aforementioned agents in antidepressant augmentation. We then compared the approximate out-of-pocket ...
Source: Journal of Clinical Psychopharmacology - July 1, 2020 Category: Psychiatry Tags: Brief Reports Source Type: research

The effect of apatinib on pharmacokinetic profile of buspirone both in vivo and in vitro
ConclusionsApatinib suppresses the CYP450 based metabolism of buspirone in a mixed mechanism and boosted the blood exposure of prototype drug and 6 ‐OH buspirone dramatically. Therefore, extra caution should be taken when combining apatinib with buspirone in clinic. (Source: Journal of Pharmacy and Pharmacology)
Source: Journal of Pharmacy and Pharmacology - June 29, 2020 Category: Drugs & Pharmacology Authors: Xiao ‐dan Zhang, Ying‐hui Li, Dao‐xing Chen, Wei‐wei You, Xiao‐xia Hu, Bing‐bing Chen, Guo‐xin Hu, Jian‐chang Qian Tags: Research Paper Source Type: research

Expression of serotonin 1A and 2A receptors in molecular- and projection-defined neurons of the mouse insular cortex
The serotonin (5-HT) system is the target of multiple anxiolytics, including Buspirone, which is a partial agonist of the serotonin 1A receptor (5-HT1A). Similarly, ligands of the serotonin 2A receptor (5-HT2A... (Source: Molecular Brain)
Source: Molecular Brain - June 29, 2020 Category: Neuroscience Authors: Anes Ju, Beatriz Fernandez-Arroyo, Yifan Wu, D ébora Jacky and Anna Beyeler Tags: Research Source Type: research

Serotonergic treatment normalizes midbrain dopaminergic neuron increase after periaqueductal gray stimulation.
In this study, we further analysed our previous data on the effects of escitalopram (a selective serotonin reuptake inhibitor, SSRI) and buspirone (a 5-HT1A receptor partial agonist) on dlPAG-induced anticipatory fear behaviour in a rat model using freezing as a measure. We then attempted to unravel some of the interactions with dopamine signalling using tyrosine hydroxylase (TH) immunohistochemistry to probe the effects on dopaminergic neurons. We showed that acute treatment of escitalopram, but not buspirone, was effective in reducing anticipatory freezing behaviour, while chronic administrations of both drugs were effec...
Source: Brain Structure and Function - June 26, 2020 Category: Neuroscience Authors: Tan SZK, Temel Y, Chan AY, Mok ATC, Perucho JAU, Blokland A, Aquili L, Lim WL, Lim LW Tags: Brain Struct Funct Source Type: research

Serotonergic treatment normalizes midbrain dopaminergic neuron increase after periaqueductal gray stimulation
In this study, we further analysed our previous data on the effects of escitalopram (a selective serotonin reuptake inhibitor, SSRI) and buspirone (a 5-HT1A receptor partial agonist) on dlPAG-induced anticipatory fear behaviour in a rat model using freezing as a measure. We then attempted to unravel some of the interactions with dopamine signalling using tyrosine hydroxylase (TH) immunohistochemistry to probe the effects on dopaminergic neurons. We showed that acute treatment of escitalopram, but not buspirone, was effective in reducing anticipatory freezing behaviour, while chronic administrations of both drugs were effec...
Source: Anatomy and Embryology - June 26, 2020 Category: Anatomy Source Type: research

Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial
ConclusionsBuspirone reduces CO2 chemosensitivity and improves CA and oxygen saturation across the 24  h in patients with HF. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - May 21, 2020 Category: Cardiology Authors: Alberto Giannoni, Chiara Borrelli, Gianluca Mirizzi, George B. Richerson, Michele Emdin, Claudio Passino Tags: Research Article Source Type: research

Primary orthostatic tremor in mandible: A rare case report
Mauricio Kosminsky, Eduardo Grossmann, Rodrigo Lorenzi PoluhaIndian Journal of Dental Research 2020 31(2):315-317 Primary orthostatic tremor (POT) is a rare movement disorder of unknown pathophysiology, characterized by fast tremor affecting a specific part of the body. The present paper reports a case of POT in mandible, discussing the approach and management. A 37-year-old male patient complained of involuntary mandibular movements, with onset 6 years ago, with no history of precipitating event. Usually, tremors were not present during patient's mastication or phonation. The oscillations presented rhythmically and s...
Source: Indian Journal of Dental Research - May 18, 2020 Category: Dentistry Authors: Mauricio Kosminsky Eduardo Grossmann Rodrigo Lorenzi Poluha Source Type: research

Inadequate Response to Treatment in Major Depressive Disorder: Augmentation and Adjunctive Strategies.
Authors: Rafeyan R, Papakostas GI, Jackson WC, Trivedi MH Abstract ​​​​ About 30%-50% of patients experience inadequate response to antidepressant therapy, and treatment choices for these patients include augmenting the antidepressant with another therapy, increasing the dose, switching to a different antidepressant, or combining antidepressants. Clinicians should tailor treatment strategies based on patients' response, tolerability, and disease severity. In this activity, augmentation and adjunctive strategies involving atypical antipsychotics, as well as off-label options including buspirone, stimulants, ...
Source: Journal of Clinical Psychiatry - May 17, 2020 Category: Psychiatry Tags: J Clin Psychiatry Source Type: research

A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
In this study, we aimed to evaluate the efficacy and tolerability of aripiprazole and quetiapine as augmentative treatments in patients with selective serotonin reuptake inhibitor (SSRI) refractory OCD. The OCD patients were initially treated for 12 weeks with a SSRI. If after 12 weeks their Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score was more than 16, they were randomly assigned to either the aripiprazole or the quetiapine augmentation group for an additional 12 weeks. There were no significant differences in age, sex, education, marital status, or score of Y-BOCS and Clinical Global Impression-Severity Scale (CG...
Source: Canadian Journal of Physiology and Pharmacology - March 31, 2020 Category: Drugs & Pharmacology Authors: Talaei A, Hosseini FF, Aghili Z, Akhondzadeh S, Asadpour E, Mehramiz NJ, Forouzanfar F Tags: Can J Physiol Pharmacol Source Type: research

The Hypothesis on the Prediction of Treatment Response with Buspirone Augmentation along with Serotonergic Antidepressant in Patients with Major Depressive Disorder Using Loudness Dependence of Auditory Evoked Potentials: Two Cases and Review of the Literature for Evidence.
Authors: Park YM Abstract Some studies have shown that augmenting buspirone with antidepressant has similar efficacy as the combination with two antidepressants in patients with major depressive disorder (MDD). Some researchers assume that the antidepressant boosting effect of buspirone is revealed under a poop-out state, which means a phenomenon where some patients having an initial response to an antidepressant may worsen or not improve any more even though they continue treatment because of serotonin depletion. Loudness dependence of auditory evoked potential (LDAEP) is a reliable marker of central serotonergic ...
Source: Psychiatry Investigation - March 12, 2020 Category: Psychiatry Tags: Psychiatry Investig Source Type: research

Pharmacotherapy for the Treatment of Cannabis Use Disorder: A Systematic Review.
Conclusion: Although data on pharmacologic interventions for CUD are scarce, evidence exists that several drug classes, including cannabinoids and SSRIs, are ineffective. Because of increasing access to and use of cannabis in the general population, along with a high prevalence of CUD among current cannabis users, an urgent need exists for more research to identify effective pharmacologic treatments. Primary Funding Source: U.S. Department of Veterans Affairs. (PROSPERO: CRD42018108064). PMID: 32120384 [PubMed - as supplied by publisher] (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - March 2, 2020 Category: Internal Medicine Authors: Kondo KK, Morasco BJ, Nugent SM, Ayers CK, O'Neil ME, Freeman M, Kansagara D Tags: Ann Intern Med Source Type: research

Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats
ConclusionsElacridar is useful for distinguishing the contribution of P-gp from CYP3A to the absorption of drugs in rats. The in vivo contribution of P-gp is minimal for high permeable compounds owing to their fraction absorbed of nearly 1.0. (Source: European Journal of Drug Metabolism and Pharmacokinetics)
Source: European Journal of Drug Metabolism and Pharmacokinetics - February 19, 2020 Category: Drugs & Pharmacology Source Type: research

Somatosensorimotor and odor modification, along with serotonergic processes underlying the social deficits in BTBR T+ Itpr3tf/J and BALB/cJ mouse models of autism
Publication date: Available online 13 February 2020Source: NeuroscienceAuthor(s): Hiroyuki ArakawaAbstractAutism is a complex spectrum of disorders characterized by core behavioral deficits in social communicative behavior, which are also required for comprehensive analysis of preclinical mouse models. As animal models of the core behavioral deficits in autism, two inbred mouse strains, BTBR T+ Itpr3tf/J (BTBR) and BALB/cJ (BALB), were compared with the standard social strain, C57BL/6J (B6), regarding a variety of behavioral factors underlying social communicative interactions, including olfactory and tactile sensory proce...
Source: Neuroscience - February 13, 2020 Category: Neuroscience Source Type: research

Pharmacological treatments for social anxiety disorder in adults: a systematic review and network meta-analysis.
CONCLUSION: The differences between drugs and placebo were small, apart from a significant reduction in symptom severity and response for paroxetine. We suggest paroxetine as a first line treatment of SAD, with the consideration of future research on the drug olanzapine as well as brofaromine, bromazepam, clonazepam, escitalopram, fluvoxamine, phenelzine, and sertraline because we observed a response to treatment. PMID: 32039743 [PubMed - as supplied by publisher] (Source: Acta Neuropsychiatrica)
Source: Acta Neuropsychiatrica - February 11, 2020 Category: Psychiatry Tags: Acta Neuropsychiatr Source Type: research

Current and Novel Psychopharmacological Drugs for Anxiety Disorders.
Authors: Bandelow B Abstract Anxiety disorders, including panic disorder/agoraphobia (PDA), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and others, are the most prevalent mental disorders. In this paper, recommendations are given for the psychopharmacological treatment of these disorders which are based on comprehensive treatment guidelines, meta-analyses, and systematic reviews of available randomized controlled studies. Anxiety disorders can effectively be treated with psychotherapy, pharmacotherapy, or a combination of both. First-line drugs are the selective serotonin reuptake inhibitors ...
Source: Advances in Experimental Medicine and Biology - February 2, 2020 Category: Research Tags: Adv Exp Med Biol Source Type: research

Drugs for Depression
Date: February 24, 2020 Issue #:  1592Summary:  Complete remission of symptoms is the goal of treatment for major depressive disorder; a partial response is associated with an increased risk of relapse. Improvement in symptoms can occur within the first two weeks of treatment with an antidepressant, but it may take 4-8 weeks to achieve a substantial benefit. Following successful treatment of a first major depressive episode, antidepressant treatment should be continued at the same dose for at least 4-9 months to consolidate recovery. In patients with recurrent depressive episodes, long-term mai...
Source: The Medical Letter - January 17, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Abilify Amitriptyline Amoxapine Antidepressants Antipsychotics aplenzin Aripiprazole Aventyl brexanolone brexpiprazole Bupropion BuSpar Buspirone Celexa Cipralex Citalopram Cymbalta Deep Brain stimulation Deplin Depre Source Type: research

Pharmacological interventions for treatment-resistant depression in adults.
CONCLUSIONS: A small body of evidence shows that augmenting current antidepressant therapy with mianserin or with an antipsychotic (cariprazine, olanzapine, quetiapine or ziprasidone) improves depressive symptoms over the short-term (8 to 12 weeks). However, this evidence is mostly of low or moderate quality due to imprecision of the estimates of effects. Improvements with antipsychotics need to be balanced against the increased likelihood of dropping out of treatment or experiencing an adverse event. Augmentation of current antidepressant therapy with a second antidepressant, mirtazapine, does not produce a clinically imp...
Source: Cochrane Database of Systematic Reviews - December 16, 2019 Category: General Medicine Authors: Davies P, Ijaz S, Williams CJ, Kessler D, Lewis G, Wiles N Tags: Cochrane Database Syst Rev Source Type: research

Behavioral effects of buspirone in a mouse model of posttraumatic stress disorder.
Abstract Buspirone presents a unique profile of action, which involves activation of 5-HT1A receptors and complex effects on D2-like dopaminergic receptors. This medication is studied in terms of potential clinical repositioning to conditions that are associated with dopaminergic dysfunctions including schizophrenia and substance use disorder. Buspirone antagonizes D3 and D4 receptors, however, depending on the dose it differentially interacts with D2 receptors. Previously, we reported that some of D2/D3 dopaminergic agonists attenuate PTSD-like behavioral symptoms in mice. Here we investigated whether buspirone c...
Source: Behavioural Brain Research - November 21, 2019 Category: Neurology Authors: Malikowska-Racia N, Popik P, Sałat K Tags: Behav Brain Res Source Type: research

Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series.
Abstract Co-morbid anxiety disorders, including generalized anxiety disorder (GAD), are highly prevalent among individuals with Williams syndrome (WS). However, reports of the pharmacologic treatment of only a limited number of previous anxiety disorders in WS have appeared in the literature. Here, we review the case histories of three adolescents/young adults with WS and the treatment course of co-morbid GAD with buspirone. Treatment with buspirone was well-tolerated and resulted in sustained response in all three cases. Common medical disorders in WS are highlighted with regards to safe and appropriate pharmacol...
Source: Journal of Autism and Developmental Disorders - November 13, 2019 Category: Psychiatry Authors: Thom RP, Keary CJ, Waxler JL, Pober BR, McDougle CJ Tags: J Autism Dev Disord Source Type: research

Herbal Medicine of the 21st Century: A Focus on the Chemistry, Pharmacokinetics and Toxicity of Five Widely Advocated Phytotherapies.
CONCLUSION: The potentiation of the activity of concurrently administered conventional agents is potentially lethal especially if the drug bear dangerous side effects and low therapeutic windows. PMID: 31721714 [PubMed - as supplied by publisher] (Source: Current Topics in Medicinal Chemistry)
Source: Current Topics in Medicinal Chemistry - November 11, 2019 Category: Chemistry Authors: Suroowan S, Mahomoodally MF Tags: Curr Top Med Chem Source Type: research

The role of high-resolution manometry in the assessment of upper gastrointestinal involvement in systemic sclerosis: a systematic review
The objectives of this systematic review were to investigate the role of HRM in the assessment of SSc-associated upper GI involvement and to evaluate the correlation between HRM abnormalities and clinical characteristics and the effects of therapeutic interventions on HRM findings. Fifteen articles were included. Most (11/15) studies were of very good or good quality. Most studies assessed correlations between esophageal symptoms and esophageal dysmotility. Two studies assessed the effectiveness of buspirone and reported HRM findings. Studies assessing upper GI symptoms using validated questionnaires, such as the Universit...
Source: Clinical Rheumatology - November 10, 2019 Category: Rheumatology Source Type: research

Buspirone/ciclosporin
(Source: Reactions Weekly)
Source: Reactions Weekly - October 31, 2019 Category: Drugs & Pharmacology Source Type: research

Blonanserin Suppresses Impulsive Action in Rats
Publication date: Available online 21 October 2019Source: Journal of Pharmacological SciencesAuthor(s): Naoya Nishitani, Hitomi Sasamori, Yu Ohmura, Takayuki Yoshida, Mitsuhiro YoshiokaAbstractHigh impulsivity will increase the risk of criminal behavior, drug abuse, and suicide. We chose two drugs by following a strategy recently we proposed for identifying potential anti-impulsivity drugs, and examined the effects on impulsive action in rats by using a 3-choice serial reaction time task. We showed that the administration of blonanserin, an atypical antipsychotic, reduced impulsive actions in a U-shaped manner. 1-(2-Pyriid...
Source: Journal of Pharmacological Sciences - October 21, 2019 Category: Drugs & Pharmacology Source Type: research

26.4 a retrospective chart review of buspirone for the treatment of anxiety in psychiatrically referred youth with high-functioning asd
Anxiety disorders (ADs) are commonly associated with high-functioning ASD (HF-ASD) and often worsen with age. However, pharmacological treatment trials for anxiety in this population are lacking. This presentation will provide a brief overview of the existing pharmacological evidence for treating anxiety in ASD. Additionally, new data on the efficacy of buspirone, a commonly prescribed anxiolytic drug with a favorable tolerability profile, will be presented. (Source: Journal of the American Academy of Child and Adolescent Psychiatry)
Source: Journal of the American Academy of Child and Adolescent Psychiatry - September 30, 2019 Category: Psychiatry Authors: Gagan Joshi Source Type: research

The effect of acute and repeated administration of buspirone, 8-OHDPAT and fluoxetine on haloperidol-induced extrapyramidal symptoms.
CONCLUSION: It may be concluded that buspirone and 8-OHDPAT improves extrapyramidal symptoms in a haloperidol-induced Parkinsonism model probably via activation of 5-HT₁A receptors. However, further investigations should be carried out to clarify the exact mechanism of interaction between 5-HT₁A and DA receptors. PMID: 31378723 [PubMed - in process] (Source: Neuropsychopharmacologia Hungarica)
Source: Neuropsychopharmacologia Hungarica - August 7, 2019 Category: Psychiatry Tags: Neuropsychopharmacol Hung Source Type: research

Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability.
ska A Abstract On the basis of the structures of serotonin modulators or drugs (NAN-190, buspirone, aripiprazole) and phosphodiesterase 4 (PDE4) inhibitors (rolipram, RO-20-1724), a series of novel multitarget 5-arylidenehydantoin derivatives with arylpiperazine fragment was synthesized. Among these compounds, 5-(3,4-dimethoxybenzylidene-3-(4-(4-(2,3-dichlorophenyl)piperazine-1-yl)butyl)-imidazolidine-2,4-dione (13) and 5-(3-cyclopentyloxy-4-methoxybenzylidene-3-(4-(4-(2-methoxyphenyl)piperazine-1-yl)butyl)-imidazolidine-2,4-dione (18) were found to be the most promising showing very high affinity toward 5-HT1A an...
Source: Bioorganic and Medicinal Chemistry - July 29, 2019 Category: Chemistry Authors: Czopek A, Bucki A, Kołaczkowski M, Zagórska A, Drop M, Pawłowski M, Siwek A, Głuch-Lutwin M, Pękala E, Chrzanowska A, Struga M, Partyka A, Wesołowska A Tags: Bioorg Med Chem Source Type: research